Serlift (sertraline) coated tablets 100 mg. №28

Description

Serlift (sertraline) coated tablets 100 mg. №28

Composition

active substance: sertraline;

1 tablet contains sertraline hydrochloride 55.96 mg equivalent to sertraline 50 mg or sertraline hydrochloride 111.92 mg equivalent to sertraline 100 mg;

excipients: calcium hydrogen phosphate, microcrystalline cellulose, hydroxypropyl cellulose-L, sodium starch glycolate (type A), magnesium stearate, hypromellose, titanium dioxide (E 171), macrogol 400, talc.

Medicinal form

Coated tablets.

The main physical and chemical properties:

• tablets of 50 mg: white tablets of an elongated shape, covered with a shell, marked “50” on one side and a dividing line on the other;
• tablets of 100 mg: white tablets of an elongated shape, covered with a shell, marked “100” on one side and a dividing line on the other.

Pharmacotherapeutic group

Antidepressants. Selective serotonin reuptake inhibitors.
ATX code N06A B06.

Pharmacological properties

Sertraline is a potent and specific inhibitor of the neuronal uptake of serotonin (5-HT) in vitro, which in animals leads to the potentiation of the effects of 5-HT. Sertraline has only a very weak effect on the processes of neuronal reuptake of norepinephrine and dopamine. At clinical doses, sertraline blocks the uptake of serotonin in human platelets. The drug does not show stimulating, sedative, anticholinergic or cardiotoxic effects in experiments on animals. In controlled studies with the participation of healthy volunteers, sertraline did not have a sedative effect and did not affect psychomotor functions. Due to its inherent selective inhibition of 5-HT reuptake, sertraline does not stimulate catecholaminergic activity. The tool has no affinity for muscarinic (cholinergic), serotonergic, dopaminergic, adrenergic, histaminergic, GABA or benzodiazepine receptors. Long-term use of sertraline in animals led to a decrease in the activity of noradrenaline receptors in the brain, which is also observed with the use of other clinically effective antidepressants and anti-obsessive drugs.

Indications

The drug Serlift tablets is used to treat and prevent relapse of depressive conditions (from mild to severe), including those that are accompanied by the risk of a suicidal attempt, anxiety.
Also, this drug is indicated for PTSD (post-traumatic stress disorder), OCD (obsessive-compulsive disorder), panic disorders (with / without agoraphobia or other phobia), anorexia nervosa, chronic pain syndromes, bulimia.

Contraindications

Serlift tablets should not be used in case of hypersensitivity to it, epilepsy (with exacerbation), children under six years old, pregnant women, breastfeeding.
It is also prohibited to take the drug Serlift and MAO inhibitors at the same time.

Application during pregnancy and lactation

The use of the drug Serlift during the indicated periods is prohibited.

Method of administration and dosage

The starting standard dose of this drug is 50 mg / day in one dose. The remedy is obtained regardless of food.
The initial effect can be seen as early as seven days after starting therapy, but the full effect of this drug usually appears after two to four weeks. If there is no effect after several weeks from the start of therapy, you can gradually increase the dose (by 50 mg per week); the maximum dose of Surlift is 200 mg / day.
With long-term therapy, the patient must individually select the minimum effective maintenance dose.
Serlift tablets should not be used in conjunction with drugs of the MAO inhibitor group and within fourteen days after stopping treatment with them. Similarly, after canceling Surlift, MAO inhibitors should not be taken for fourteen days.

Overdose

Symptoms of a Surlift overdose include: disorientation, anxiety, tremors, restlessness, muscle hypertonicity, dilated pupils, increased reflexes, abdominal cramps, increased heart rate, myoclonic twitching, drowsiness, flatulence, nausea, diarrhea, vomiting, dyspepsia.
In the first hour in case of an overdose with Serlift, gastric lavage should be performed, then adsorbents should be given. Further, it is required to ensure the patient’s airway patency. Control of the functions of vital organs is necessary; symptomatic treatment is indicated. There is no specific antidote.

Side effects

When using Serlift, the patient may experience allergic reactions, decreased appetite, the development of bleeding (nasal, etc.), weight loss, increased appetite (rare), the occurrence of nausea, hypomania and mania, palpitations, dry mouth, vomiting, diarrhea , abdominal pain and cramps, flatulence, headache, dizziness, insomnia, drowsiness, tremors, coordination disorders (including gait changes, etc.), seizures, paresthesias, hallucinations, aggressiveness, agitation, anxiety, psychosis, flushing face, visual impairment, hyperhidrosis (increased sweating), sexual dysfunctions (decreased potency, anorgasmia, etc.), dysmenorrhea, galactorrhea (secretion of breast milk not associated with breastfeeding), skin rashes, itching.
Also, the development of a withdrawal syndrome is among the undesirable phenomena associated with taking the drug Serlift.